Literature DB >> 7264649

Effect of inhibitors of GABA aminotransferase on the metabolism of GABA in brain tissue and synaptosomal fractions.

W Löscher.   

Abstract

Five inhibitors of the GABA degrading enzyme GABA-aminotransferase (GABA-T), viz., gabaculine, gamma-acetylenic GABA, gamma-vinyl GABA, ethanolamine O-sulphate, and aminooxyacetic acid, as well as GABA itself and the antiepileptic sodium valproate were administered to mice in doses equieffective to raise the electroconvulsive threshold by 30 V. The animals were killed at the time of maximal anticonvulsant effect of the respective drugs and GABA, GABA-T and glutamate decarboxylase (GAD) were determined in whole brain and synaptosomes, respectively. The synaptosomal fraction was prepared from brain by conventional ultracentrifugation procedures. All drugs studied brought about significant increases in both whole brain and synaptosomal GABA concentrations, and, except GABA itself, inhibited the activity of GABA-T. Furthermore, all drugs, except GABA and gamma-acetylenic GABA, activated GAD in the synaptosomal fraction. This was most pronounced with ethanolamine O-sulphate, which induced a twofold activation of this enzyme but exerted only a weak inhibitory effect on GABA-T. The results suggest that activation of GAD is an important factor in the mechanism by which several inhibitors of GABA-T and also valproate increase GABA concentrations in nerve terminals, at least in the relatively non-toxic doses as used in this study.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7264649     DOI: 10.1111/j.1471-4159.1981.tb00595.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  22 in total

1.  Chronic administration of valproic acid induces a decrease in rat striatal glutamate and taurine levels.

Authors:  G B Acosta; S I Wikinski; C C Bonelli; M C Rubio
Journal:  Amino Acids       Date:  1996-06       Impact factor: 3.520

Review 2.  Glutamate, GABA, and CNS disease: a review.

Authors:  J E Walker
Journal:  Neurochem Res       Date:  1983-04       Impact factor: 3.996

Review 3.  GABAergic mechanisms in the pathogenesis and treatment of epilepsy.

Authors:  B S Meldrum
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

4.  The smooth muscle relaxant effect of hydrogen sulphide in vitro: evidence for a physiological role to control intestinal contractility.

Authors:  B Teague; S Asiedu; P K Moore
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

5.  "In vivo" administration of valproate decreases t-[35S]butylbicyclophosphorothionate binding in the rat brain.

Authors:  A Concas; M P Mascia; E Sanna; G Santoro; M Serra; G Biggio
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-03       Impact factor: 3.000

Review 6.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.

Authors:  Wolfgang Löscher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

7.  Accumulation of labeled gamma-aminobutyric acid into rat brain and brain synaptosomes after i.p. injection.

Authors:  L Vignolo; A Cupello; P Mainardi; M V Rapallino; A Patrone; C Loeb
Journal:  Neurochem Res       Date:  1992-02       Impact factor: 3.996

8.  Biphasic action of vigabatrin on cortical epileptic after-discharges in rats.

Authors:  Pavel Mares; Romana Slamberová
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-07       Impact factor: 3.000

9.  Evaluation of the mechanisms by which gamma-amino-butyric acid in association with phosphatidylserine exerts an antiepileptic effect in the rat.

Authors:  E Benassi; G Besio; A Cupello; P Mainardi; A Patrone; M V Rapallino; L Vignolo; C W Loeb
Journal:  Neurochem Res       Date:  1992-12       Impact factor: 3.996

10.  On the existence of two GABA pools associated with newly synthesized GABA and with newly taken up GABA in nerve terminals.

Authors:  M Abe; M Matsuda
Journal:  Neurochem Res       Date:  1983-05       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.